BioPharma Resources

Drug Trial Radar · NCT06568484

Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB

Bedaquiline Roll-out Evidence in Contacts and People Living With HIV to Prevent TB (BREACH-TB)

Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 2,530 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

2,530

Planned (sponsor's estimate)

Start

May 8, 2026

Primary completion

Jul 2027

Study completion Sep 2027

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Elizabeth Glaser Pediatric AIDS Foundation; US Department of State
First posted
Aug 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A seamless, staged Phase II/III, open-label, multicenter, non-inferiority trial, to compare the efficacy and safety of 4 weeks of bedaquiline (BDQ) versus a a standard regimen for preventing regimen for preventing confirmed or probable tuberculosis disease (TBD) during 72 weeks of follow-up among people living with HIV (PLHIV) and high-risk Close Contacts (CC) of adults with Drug Susceptible (DS) or Rifampin Resistant (RR) TB.

Conditions

  • Tuberculosis, Latent

Interventions

  • BedaquilineDrug

    CCs (Close Contacts) of DS-TB Index Patients and PLHIV at high risk of developing TBD 1. Children 0 to \<5 years old who are HIV negative, regardless of latent tuberculosis infection (LTBI) result by TST (tuberculin skin test) or IGRA (interferon-gamma release assay) 2. Adults, pregnant people, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA) 3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether the participant is a CC CCs of RR-TB Index Patients at high risk of developing TBD 1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA) 2. Adults, adolescents, and children ≥5 years old who are HIV negative and LTBI positive (by IGRA) 3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status Bedaquiline based on weight and/or age at Enrollment daily for four weeks (28 doses)

  • Isoniazid, rifapentineCombination product

    CCs of DS-TB Index Patients and PLHIV at high risk of developing TBD 1. Children 0 to \<5 years old who are HIV status negative, regardless of latent tuberculosis infection (LTBI) result (WHO-recommended skin test or interferon-gamma release assay \[IGRA\]) 2. Adults, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA) 3. Adults and adolescents ≥15 years of age who are living with HIV regardless of LTBI status, regardless of whether they are a CC 3HP: 3 months of weekly isoniazid (H) and rifapentine (P) (12 doses)

  • LevofloxacinDrug

    CCs of RR-TB Index Patients at high risk of developing TBD 1. Children 0 to \<5 years old, regardless of HIV status or LTBI result (by TST or IGRA) 2. Adults, adolescents, and children ≥5 years old who are HIV status negative and LTBI positive (by IGRA) 3. Adults, pregnant people, adolescents, and children ≥5 years old who are living with HIV regardless of LTBI status Levofloxacin (LFX) based on weight at Enrollment daily for 6 months (182 doses)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety DS-TB CCs and PLHIV (Stage 1): Proportion of participants who permanently discontinue the randomized study drug due to a treatment-related adverse event by 18 weeksTime frame: 18 weeks
  2. Safety for RR-TB CCs (Stage 1): Proportion of participants who permanently discontinue the randomized study drug due to a treatment-related adverse event by 36 weeksTime frame: 36 weeks
  3. Treatment Completion - PLHIV & CCs of DS-TB (Stage 1): Proportion of participants completing assigned treatment within window prescribed in protocolTime frame: 18 weeks
  4. Treatment Completion - CCs of RR-TB (Stage 1): Proportion of participants completing assigned treatment within window prescribed in protocolTime frame: 36 weeks
  5. Primary Efficacy Endpoint (Stage 2): Number of enrolled participants (PLHIV, contacts of DS-TB or RR-TB) diagnosed with bacteriologically confirmed or probable / (if adult), and confirmed or unconfirmed (if child) TB diseaseTime frame: Up to 72 weeks post-treatment initiation
  6. Primary Safety Endpoint (Stage 2): Cumulative number of enrolled participants (PLHIV, contacts of DS-TB or RR-TB) who permanently discontinue the assigned study regimen due to an adverse drug reactionTime frame: Varies by treatment regimen (1 month, 3 months, or 6 months)

Locations

8 sites in 4 countries. Site status is shown where the registry gives one.

  • National Center for Communicable Disease (NCCD)

    Ulaanbaatar, Mongolia · Not yet recruiting

  • HNSEB (Hospital Nacional Sergio E. Bernales)

    Lima, Peru · Recruiting

  • SES Policlinico

    Lima, Peru · Recruiting

  • Nimr-Mmrc

    Mbeya, Tanzania · Not yet recruiting

  • Kilimanjaro Clinical Research Institute

    Moshi, Tanzania · Recruiting

  • Joint Clinical Research Centre

    Kampala, Uganda · Recruiting

  • Makerere Lung Institute

    Kampala, Uganda · Recruiting

  • MU-JHU Care Ltd.

    Kampala, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.